ABL Diagnostics has disclosed the total number of voting rights and shares composing its share capital as of May 22, 2026. The company reported 16,114,656 shares outstanding, providing transparency on its equity structure for shareholders and regulatory bodies.

The filing details the breakdown of voting rights, distinguishing between theoretical and exercisable figures. Theoretical voting rights are calculated on the basis of all shares to which voting rights are attached, including shares deprived of voting rights. In accordance with resolutions dated March 23, 2022, double voting rights are granted to all fully paid-up shares for which a registered holding in the name of the same shareholder for at least two years has been evidenced, effective from March 23, 2022.

The following table outlines the share capital and voting rights data:

| Date | Total number of shares composing the share capital | Total number of voting rights (1) (2) || | :--- | :--- | :--- | :--- || | | | Theoretical voting rights | Exercisable voting rights || | 22 mai 2026 | 16 114 656 | 30 846 644 | 30 814 120 ||

ABL Diagnostics specializes in innovative molecular biology tests and global solutions, including molecular polymerase chain reaction (PCR) detection under the UltraGene brand and genotyping by DNA sequencing under the DeepChek® brand. The company markets its products globally through its own sales team and a network of exclusive distributors.

The company's expanding portfolio includes HIV drug resistance testing, SARS-CoV-2, Tuberculosis, Hepatitis B and C detection solutions, and microbiome analyses. ABL Diagnostics has been marketing the products and services of its sister company CDL Pharma since the second half of 2025 through an intra-group strategy agreement.

ABL Diagnostics is headquartered in Woippy and is listed on compartment B of the regulated market of Euronext in Paris (Euronext: ABLD – ISIN: FR001400AHX6).

ABL Diagnostics has called its Ordinary and Extraordinary General Meeting for June 30, 2026, at 11:00 a.m. in Paris to approve the annual financial statements for the financial year ended December 31, 2025. The meeting will take place at the premises of the law firm De Gaulle Fleurance & Associates, located at 9 rue Boissy d'Anglas – 75008 Paris.

The Board will seek shareholder approval on the audited accounts for FY25. The preliminary notice of meeting, including the agenda, the text of the resolutions, and the main procedures for participation and voting, was published in the Bulletin des Annonces Légales Obligatoires (BALO) on May 22, 2026.

Meeting Details

Shareholders can access the notice of meeting and all related documents referred to in Article R.22-10-23 of the French Commercial Code on the company's website. The following table outlines the key event details:

About ABL Diagnostics

ABL Diagnostics specializes in innovative molecular biology tests and global solutions, including Molecular polymerase chain reaction (PCR) detection under the UltraGene brand and genotyping by DNA sequencing under the DeepChek® brand. The company markets its products globally through its own sales team and a network of exclusive distributors.

The company's portfolio includes HIV drug resistance testing, SARS-CoV-2, Tuberculosis, Hepatitis B and C detection solutions, and microbiome analyses. ABL Diagnostics has been marketing the products and services of its sister company CDL Pharma since the second half of 2025 through an intra-group strategy agreement. The company is listed on Euronext in Paris (ISIN: FR001400AHX6).